Yttrium-90 transarterial radioembolization for chemotherapy-refractory intrahepatic cholangiocarcinoma: a prospective, observational study
Slevin, Nicholas J
AffiliationCedar, Cardiff & Vale University Health Board, Cardiff Medicentre, Heath Park, Cardiff
MetadataShow full item record
AbstractPURPOSE: To evaluate the safety and efficacy of yttrium-90 transarterial radioembolization (TARE) for the treatment of unresectable, chemotherapy-refractory intrahepatic cholangiocarcinoma (ICC). METHODS: A prospective, observational study was carried out in 10 centers between 2013 and 2017. TARE plus standard care was delivered to patients with unresectable, chemotherapy-refractory or chemotherapy-intolerant ICC. Primary outcome was overall survivaL Secondary outcomes included safety, progression-free survival (PFS), and liver-specific progression-free survival (LPFS). RESULTS: Sixty-one patients were treated with TARE Patients were 53% male; median age was 64 years; 91% had performance status 0/1; 92% had received prior chemotherapy; and 59% had no extrahepatic disease. Median follow-up was 13.9 months (95% confidence interval [CI], 9.6-18.1). Overall survival was 8.7 months (95% CI, 5.3-12.1), and 37% of patients survived to 12 monthS PFS was 2.8 months (95% CI, 2.6-3.1), and LPFS was 3.1 months (95% CI, 1.3-4.8). One severe complication (abdominal pain) occurred at the time of the TARE procedure. Thirty patients experienced a total of 49 adverse events, of which 8% were grade >/=3; most common were grade 1-2 fatigue and abdominal pain. A total of 77 abnormal laboratory value events were recorded, of which 4% were grade >/=3. CONCLUSIONS: Patients with advanced ICC have limited therapeutic options and a poor prognosis. This prospective study examined the survival of patients with unresectable, chemotherapy-refractory primary ICC treated with TARE in real-world practice. The results demonstrate that this treatment merits further investigation in this patient cohort in a larger study, including collection of patient-reported outcomes.
CitationWhite J, Carolan-Rees G, Dale M, Patrick HE, See TC, Bell JK, et al. Yttrium-90 transarterial radioembolization for chemotherapy-refractory intrahepatic cholangiocarcinoma: a prospective, observational study. J Vasc Interv Radiol. 2019; 30(8):1185-92.
JournalJournal of Vascular and Interventional Radiology
- Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization.
- Authors: Camacho JC, Kokabi N, Xing M, Prajapati HJ, El-Rayes B, Kim HS
- Issue date: 2014 Feb
- Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study.
- Authors: Gangi A, Shah J, Hatfield N, Smith J, Sweeney J, Choi J, El-Haddad G, Biebel B, Parikh N, Arslan B, Hoffe SE, Frakes JM, Springett GM, Anaya DA, Malafa M, Chen DT, Chen Y, Kim RD, Shridhar R, Kis B
- Issue date: 2018 Aug
- Yttrium-90 microsphere radioembolization in unresectable intrahepatic cholangiocarcinoma.
- Authors: Mosconi C, Cappelli A, Ascanio S, Pettinari I, Modestino F, Renzulli M, Galaverni MC, Cucchetti A, Gramenzi A, Pettinato C, Golfieri R
- Issue date: 2017 Jun
- Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Analysis.
- Authors: Buettner S, Braat AJAT, Margonis GA, Brown DB, Taylor KB, Borgmann AJ, Kappadath SC, Mahvash A, IJzermans JNM, Weiss MJ, Lamarca A, Bell JK, Valle JW, Hagendoorn J, Koerkamp BG, Sze DY, Lam MGEH
- Issue date: 2020 Jul
- Resin-based Yttrium-90 microspheres for unresectable and failed first-line chemotherapy intrahepatic cholangiocarcinoma: preliminary results.
- Authors: Jia Z, Paz-Fumagalli R, Frey G, Sella DM, McKinney JM, Wang W
- Issue date: 2017 Mar